IGC logo

IGC
IGC Pharma Inc

30,182
Mkt Cap
$33.66M
Volume
456,202.00
52W High
$0.4985
52W Low
$0.2525
PE Ratio
-4.56
IGC Fundamentals
Price
$0.356
Prev Close
$0.366
Open
$0.3656
50D MA
$0.404
Beta
0.51
Avg. Volume
843,805.65
EPS (Annual)
-$0.0931
P/B
5.07
Rev/Employee
$18,157.14
Loading...
Loading...
News
all
press releases
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23h ago
News Placeholder
More News
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·20d ago
News Placeholder
Best Momentum Stocks to Buy for Oct. 24
ASM, IGC and RY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 24, 2025.
Zacks·20d ago
News Placeholder
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
Zacks·21d ago
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +33.33% and -0.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Hyperfine (HYPR) delivered earnings and revenue surprises of 0.00% and -7.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +102.86% and +154.04%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of +50.00% and +6.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago

Latest IGC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.